ID   PRDX6_HUMAN             Reviewed;         224 AA.
AC   P30041; A8JZY7; P32077; Q5TAH4; Q5ZEZ8;
DT   01-APR-1993, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   07-APR-2021, entry version 218.
DE   RecName: Full=Peroxiredoxin-6;
DE            EC=1.11.1.27 {ECO:0000269|PubMed:10893423, ECO:0000269|PubMed:9497358};
DE   AltName: Full=1-Cys peroxiredoxin;
DE            Short=1-Cys PRX;
DE   AltName: Full=24 kDa protein;
DE   AltName: Full=Acidic calcium-independent phospholipase A2;
DE            Short=aiPLA2;
DE            EC=3.1.1.4 {ECO:0000269|PubMed:10893423, ECO:0000269|PubMed:26830860};
DE   AltName: Full=Antioxidant protein 2;
DE   AltName: Full=Glutathione-dependent peroxiredoxin {ECO:0000305};
DE   AltName: Full=Liver 2D page spot 40;
DE   AltName: Full=Lysophosphatidylcholine acyltransferase 5 {ECO:0000303|PubMed:26830860};
DE            Short=LPC acyltransferase 5;
DE            Short=LPCAT-5;
DE            Short=Lyso-PC acyltransferase 5;
DE            EC=2.3.1.23 {ECO:0000269|PubMed:26830860};
DE   AltName: Full=Non-selenium glutathione peroxidase;
DE            Short=NSGPx;
DE   AltName: Full=Red blood cells page spot 12;
GN   Name=PRDX6; Synonyms=AOP2, KIAA0106;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=8999971; DOI=10.1074/jbc.272.4.2542;
RA   Kim T.-S., Sundaresh C.S., Feinstein S.I., Dodia C., Skach W.R., Jain M.K.,
RA   Nagase T., Seki N., Ishikawa K., Nomura N., Fisher A.B.;
RT   "Identification of a human cDNA clone for lysosomal type Ca2+-independent
RT   phospholipase A2 and properties of the expressed protein.";
RL   J. Biol. Chem. 272:2542-2550(1997).
RN   [2]
RP   ERRATUM OF PUBMED:8999971.
RA   Kim T.-S., Sundaresh C.S., Feinstein S.I., Dodia C., Skach W.R., Jain M.K.,
RA   Nagase T., Seki N., Ishikawa K., Nomura N., Fisher A.B.;
RL   J. Biol. Chem. 272:10981-10981(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=9050990; DOI=10.1038/sj.onc.1200905;
RA   Frank S., Munz B., Werner S.;
RT   "The human homologue of a bovine non-selenium glutathione peroxidase is a
RT   novel keratinocyte growth factor-regulated gene.";
RL   Oncogene 14:915-921(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Bone marrow;
RX   PubMed=7788527; DOI=10.1093/dnares/2.1.37;
RA   Nagase T., Miyajima N., Tanaka A., Sazuka T., Seki N., Sato S., Tabata S.,
RA   Ishikawa K., Kawarabayasi Y., Kotani H., Nomura N.;
RT   "Prediction of the coding sequences of unidentified human genes. III. The
RT   coding sequences of 40 new genes (KIAA0081-KIAA0120) deduced by analysis of
RT   cDNA clones from human cell line KG-1.";
RL   DNA Res. 2:37-43(1995).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NIEHS SNPs program;
RL   Submitted (OCT-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Fetal brain, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   PROTEIN SEQUENCE OF 2-22.
RC   TISSUE=Platelet;
RX   PubMed=12665801; DOI=10.1038/nbt810;
RA   Gevaert K., Goethals M., Martens L., Van Damme J., Staes A., Thomas G.R.,
RA   Vandekerckhove J.;
RT   "Exploring proteomes and analyzing protein processing by mass spectrometric
RT   identification of sorted N-terminal peptides.";
RL   Nat. Biotechnol. 21:566-569(2003).
RN   [11]
RP   PROTEIN SEQUENCE OF 2-22; 25-53; 85-106; 133-142; 145-155; 163-173 AND
RP   175-199, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Brain, Cajal-Retzius cell, and Fetal brain cortex;
RA   Lubec G., Vishwanath V., Chen W.-Q., Sun Y.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [12]
RP   PROTEIN SEQUENCE OF 2-15.
RC   TISSUE=Liver;
RX   PubMed=1286669; DOI=10.1002/elps.11501301201;
RA   Hochstrasser D.F., Frutiger S., Paquet N., Bairoch A., Ravier F.,
RA   Pasquali C., Sanchez J.-C., Tissot J.-D., Bjellqvist B., Vargas R.,
RA   Appel R.D., Hughes G.J.;
RT   "Human liver protein map: a reference database established by
RT   microsequencing and gel comparison.";
RL   Electrophoresis 13:992-1001(1992).
RN   [13]
RP   PROTEIN SEQUENCE OF 2-13.
RC   TISSUE=Erythrocyte;
RX   PubMed=8313871; DOI=10.1002/elps.11501401183;
RA   Golaz O., Hughes G.J., Frutiger S., Paquet N., Bairoch A., Pasquali C.,
RA   Sanchez J.-C., Tissot J.-D., Appel R.D., Walzer C., Balant L.,
RA   Hochstrasser D.F.;
RT   "Plasma and red blood cell protein maps: update 1993.";
RL   Electrophoresis 14:1223-1231(1993).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 14-99.
RA   Dominguez O., Lombardia L.;
RT   "DNA probes built and sequenced for microarrays hybridisations.";
RL   Submitted (SEP-2004) to the EMBL/GenBank/DDBJ databases.
RN   [15]
RP   FUNCTION, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   CYS-47.
RX   PubMed=9497358; DOI=10.1074/jbc.273.11.6303;
RA   Kang S.W., Baines I.C., Rhee S.G.;
RT   "Characterization of a mammalian peroxiredoxin that contains one conserved
RT   cysteine.";
RL   J. Biol. Chem. 273:6303-6311(1998).
RN   [16]
RP   FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF SER-32 AND CYS-47.
RX   PubMed=10893423; DOI=10.1074/jbc.m005073200;
RA   Chen J.-W., Dodia C., Feinstein S.I., Jain M.K., Fisher A.B.;
RT   "1-Cys peroxiredoxin, a bifunctional enzyme with glutathione peroxidase and
RT   phospholipase A2 activities.";
RL   J. Biol. Chem. 275:28421-28427(2000).
RN   [17]
RP   OVEROXIDATION AT CYS-47.
RX   PubMed=12059788; DOI=10.1042/bj20020525;
RA   Wagner E., Luche S., Penna L., Chevallet M., van Dorsselaer A.,
RA   Leize-Wagner E., Rabilloud T.;
RT   "A method for detection of overoxidation of cysteines: peroxiredoxins are
RT   oxidized in vivo at the active-site cysteine during oxidative stress.";
RL   Biochem. J. 366:777-785(2002).
RN   [18]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH STH.
RX   PubMed=16186110; DOI=10.1074/jbc.m506116200;
RA   Gao L., Tse S.-W., Conrad C., Andreadis A.;
RT   "Saitohin, which is nested in the tau locus and confers allele-specific
RT   susceptibility to several neurodegenerative diseases, interacts with
RT   peroxiredoxin 6.";
RL   J. Biol. Chem. 280:39268-39272(2005).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-89, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=15592455; DOI=10.1038/nbt1046;
RA   Rush J., Moritz A., Lee K.A., Guo A., Goss V.L., Spek E.J., Zhang H.,
RA   Zha X.-M., Polakiewicz R.D., Comb M.J.;
RT   "Immunoaffinity profiling of tyrosine phosphorylation in cancer cells.";
RL   Nat. Biotechnol. 23:94-101(2005).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-44, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [21]
RP   INTERACTION WITH APEX1, IDENTIFICATION BY MASS SPECTROMETRY, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=19188445; DOI=10.1128/mcb.01337-08;
RA   Vascotto C., Fantini D., Romanello M., Cesaratto L., Deganuto M.,
RA   Leonardi A., Radicella J.P., Kelley M.R., D'Ambrosio C., Scaloni A.,
RA   Quadrifoglio F., Tell G.;
RT   "APE1/Ref-1 interacts with NPM1 within nucleoli and plays a role in the
RT   rRNA quality control process.";
RL   Mol. Cell. Biol. 29:1834-1854(2009).
RN   [22]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-63 AND LYS-209, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-44, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [25]
RP   INTERACTION WITH FAM168B.
RX   PubMed=20716133; DOI=10.1111/j.1582-4934.2010.01134.x;
RA   Mishra M., Akatsu H., Heese K.;
RT   "The novel protein MANI modulates neurogenesis and neurite-cone growth.";
RL   J. Cell. Mol. Med. 15:1713-1725(2011).
RN   [26]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22905912; DOI=10.1021/pr300539b;
RA   Rosenow A., Noben J.P., Jocken J., Kallendrusch S., Fischer-Posovszky P.,
RA   Mariman E.C., Renes J.;
RT   "Resveratrol-induced changes of the human adipocyte secretion profile.";
RL   J. Proteome Res. 11:4733-4743(2012).
RN   [27]
RP   CLEAVAGE OF INITIATOR METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.m111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C., Meinnel T.,
RA   Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [28]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-44, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [30]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [31]
RP   CLEAVAGE OF INITIATOR METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [32]
RP   FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, ACTIVITY
RP   REGULATION, AND PHOSPHORYLATION.
RX   PubMed=26830860; DOI=10.1194/jlr.m064758;
RA   Fisher A.B., Dodia C., Sorokina E.M., Li H., Zhou S., Raabe T.,
RA   Feinstein S.I.;
RT   "A novel lysophosphatidylcholine acyl transferase activity is expressed by
RT   peroxiredoxin 6.";
RL   J. Lipid Res. 57:587-596(2016).
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS), ACTIVE SITE, AND SUBUNIT.
RX   PubMed=9587003; DOI=10.1038/nsb0598-400;
RA   Choi H.-J., Kang S.W., Yang C.-H., Rhee S.G., Ryu S.-E.;
RT   "Crystal structure of a novel human peroxidase enzyme at 2.0-A
RT   resolution.";
RL   Nat. Struct. Biol. 5:400-406(1998).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 1-224, AND SUBUNIT.
RX   PubMed=27353378; DOI=10.1016/j.bbrc.2016.06.125;
RA   Kim K.H., Lee W., Kim E.E.;
RT   "Crystal structures of human peroxiredoxin 6 in different oxidation
RT   states.";
RL   Biochem. Biophys. Res. Commun. 477:717-722(2016).
CC   -!- FUNCTION: Thiol-specific peroxidase that catalyzes the reduction of
CC       hydrogen peroxide and organic hydroperoxides to water and alcohols,
CC       respectively (PubMed:9497358, PubMed:10893423). Can reduce H(2)O(2) and
CC       short chain organic, fatty acid, and phospholipid hydroperoxides
CC       (PubMed:10893423). Also has phospholipase activity, can therefore
CC       either reduce the oxidized sn-2 fatty acyl group of phospholipids
CC       (peroxidase activity) or hydrolyze the sn-2 ester bond of phospholipids
CC       (phospholipase activity) (PubMed:10893423, PubMed:26830860). These
CC       activities are dependent on binding to phospholipids at acidic pH and
CC       to oxidized phospholipds at cytosolic pH (PubMed:10893423). Plays a
CC       role in cell protection against oxidative stress by detoxifying
CC       peroxides and in phospholipid homeostasis (PubMed:10893423). Exhibits
CC       acyl-CoA-dependent lysophospholipid acyltransferase which mediates the
CC       conversion of lysophosphatidylcholine (1-acyl-sn-glycero-3-
CC       phosphocholine or LPC) into phosphatidylcholine (1,2-diacyl-sn-glycero-
CC       3-phosphocholine or PC) (PubMed:26830860). Shows a clear preference for
CC       LPC as the lysophospholipid and for palmitoyl CoA as the fatty acyl
CC       substrate (PubMed:26830860). {ECO:0000269|PubMed:10893423,
CC       ECO:0000269|PubMed:26830860, ECO:0000269|PubMed:9497358}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a hydroperoxide + 2 glutathione = an alcohol + glutathione
CC         disulfide + H2O; Xref=Rhea:RHEA:62632, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:30879, ChEBI:CHEBI:35924, ChEBI:CHEBI:57925,
CC         ChEBI:CHEBI:58297; EC=1.11.1.27;
CC         Evidence={ECO:0000269|PubMed:10893423, ECO:0000269|PubMed:9497358};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1,2-diacyl-sn-glycero-3-phosphocholine + H2O = a 1-acyl-sn-
CC         glycero-3-phosphocholine + a fatty acid + H(+); Xref=Rhea:RHEA:15801,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:28868,
CC         ChEBI:CHEBI:57643, ChEBI:CHEBI:58168; EC=3.1.1.4;
CC         Evidence={ECO:0000269|PubMed:10893423, ECO:0000269|PubMed:26830860};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1-acyl-sn-glycero-3-phosphocholine + an acyl-CoA = a 1,2-
CC         diacyl-sn-glycero-3-phosphocholine + CoA; Xref=Rhea:RHEA:12937,
CC         ChEBI:CHEBI:57287, ChEBI:CHEBI:57643, ChEBI:CHEBI:58168,
CC         ChEBI:CHEBI:58342; EC=2.3.1.23;
CC         Evidence={ECO:0000269|PubMed:26830860};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-hexadecanoyl-sn-glycero-3-phosphocholine + hexadecanoyl-CoA
CC         = 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine + CoA;
CC         Xref=Rhea:RHEA:35983, ChEBI:CHEBI:57287, ChEBI:CHEBI:57379,
CC         ChEBI:CHEBI:72998, ChEBI:CHEBI:72999;
CC         Evidence={ECO:0000269|PubMed:26830860};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:35984;
CC         Evidence={ECO:0000305|PubMed:26830860};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1,2-dihexadecanoyl-sn-glycero-3-phosphocholine + H2O = 1-
CC         hexadecanoyl-sn-glycero-3-phosphocholine + H(+) + hexadecanoate;
CC         Xref=Rhea:RHEA:41223, ChEBI:CHEBI:7896, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:72998, ChEBI:CHEBI:72999;
CC         Evidence={ECO:0000269|PubMed:26830860};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:41224;
CC         Evidence={ECO:0000305|PubMed:26830860};
CC   -!- ACTIVITY REGULATION: MJ33 or lithium;[(2R)-1-hexadecoxy-3-(2,2,2-
CC       trifluoroethoxy)propan-2-yl] methyl phosphate inhibits its
CC       phospholipase A2 activity (PubMed:26830860). CI-976 or 2,2-Dimethyl-N-
CC       (2,4,6-trimethoxyphenyl)dodecanamide inhibits its
CC       lysophosphatidylcholine acyltransferase activity (PubMed:26830860).
CC       {ECO:0000269|PubMed:26830860}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=18 uM for palmitoyl-CoA (lysophosphatidylcholine acyltransferase
CC         activity at pH 4.0) {ECO:0000269|PubMed:26830860};
CC         KM=15 uM for palmitoyl-CoA (lysophosphatidylcholine acyltransferase
CC         activity for the phosphorylated form at pH 7.0)
CC         {ECO:0000269|PubMed:26830860};
CC         Vmax=30 nmol/min/mg enzyme with palmitoyl-CoA as substrate for
CC         lysophosphatidylcholine acyltransferase activity (at pH 4.0)
CC         {ECO:0000269|PubMed:26830860};
CC         Vmax=770 nmol/min/mg enzyme with palmitoyl-CoA as substrate for
CC         lysophosphatidylcholine acyltransferase activity (phosphorylated form
CC         at pH 7.0) {ECO:0000269|PubMed:26830860};
CC       pH dependence:
CC         Shows a 3-fold greater lysophosphatidylcholine acyltransferase
CC         activity at pH 4.0 than at pH 7.0. {ECO:0000269|PubMed:26830860};
CC   -!- SUBUNIT: Homodimer (PubMed:9587003, PubMed:27353378). Interacts with
CC       GSTP1; mediates PRDX6 glutathionylation and regeneration (By
CC       similarity). Interacts with APEX1 (PubMed:19188445). Interacts with STH
CC       (PubMed:16186110). May interact with FAM168B (PubMed:20716133). May
CC       interact with HTR2A (By similarity). {ECO:0000250|UniProtKB:O08709,
CC       ECO:0000250|UniProtKB:O77834, ECO:0000269|PubMed:16186110,
CC       ECO:0000269|PubMed:19188445, ECO:0000269|PubMed:20716133,
CC       ECO:0000269|PubMed:27353378, ECO:0000269|PubMed:9587003}.
CC   -!- INTERACTION:
CC       P30041; Q9NP61: ARFGAP3; NbExp=3; IntAct=EBI-2255129, EBI-2875816;
CC       P30041; Q7KZN9: COX15; NbExp=3; IntAct=EBI-2255129, EBI-3248549;
CC       P30041; P09622: DLD; NbExp=3; IntAct=EBI-2255129, EBI-353366;
CC       P30041; P12004: PCNA; NbExp=2; IntAct=EBI-2255129, EBI-358311;
CC       P30041; P48556: PSMD8; NbExp=3; IntAct=EBI-2255129, EBI-359304;
CC       P30041; P54274: TERF1; NbExp=2; IntAct=EBI-2255129, EBI-710997;
CC       P30041; P21796: VDAC1; NbExp=3; IntAct=EBI-2255129, EBI-354158;
CC       P30041; PRO_0000308465 [P29991]; Xeno; NbExp=3; IntAct=EBI-2255129, EBI-8826747;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:16186110,
CC       ECO:0000269|PubMed:19188445, ECO:0000269|PubMed:9497358}. Lysosome
CC       {ECO:0000250|UniProtKB:O35244}. Note=Also found in lung secretory
CC       organelles (lamellar bodies). {ECO:0000250|UniProtKB:O35244}.
CC   -!- PTM: Irreversibly inactivated by overoxidation of Cys-47 to sulfinic
CC       acid (Cys-SO(2)H) and sulfonic acid (Cys-SO(3)H) forms upon oxidative
CC       stress. {ECO:0000269|PubMed:12059788, ECO:0000269|PubMed:27353378}.
CC   -!- PTM: Phosphorylation at Thr-177 by MAP kinases increases the
CC       phospholipase activity of the enzyme (By similarity). The
CC       phosphorylated form exhibits a greater lysophosphatidylcholine
CC       acyltransferase activity compared to the non-phosphorylated form
CC       (PubMed:26830860). {ECO:0000250|UniProtKB:O35244,
CC       ECO:0000269|PubMed:26830860}.
CC   -!- MISCELLANEOUS: The active site is a conserved redox-active cysteine
CC       residue, the peroxidatic cysteine (C(P)), which makes the nucleophilic
CC       attack on the peroxide substrate. The peroxide oxidizes the C(P)-SH to
CC       cysteine sulfenic acid (C(P)-SOH), which then reacts with another
CC       cysteine residue, the resolving cysteine (C(R)), to form a disulfide
CC       bridge. The disulfide is subsequently reduced by an appropriate
CC       electron donor to complete the catalytic cycle. In this 1-Cys
CC       peroxiredoxin, no C(R) is present and C(P) instead forms a disulfide
CC       with a cysteine from another protein or with a small thiol molecule.
CC       C(P) is reactivated by glutathionylation mediated by glutathione S-
CC       transferase Pi, followed by spontaneous reduction of the enzyme with
CC       glutathione. {ECO:0000250|UniProtKB:O35244}.
CC   -!- SIMILARITY: Belongs to the peroxiredoxin family. Prx6 subfamily.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=NIEHS SNPs;
CC       URL="http://egp.gs.washington.edu/data/prdx6/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; D14662; BAA03496.1; -; mRNA.
DR   EMBL; DQ230990; ABB02185.1; -; Genomic_DNA.
DR   EMBL; AL139142; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AK289352; BAF82041.1; -; mRNA.
DR   EMBL; CH471067; EAW90944.1; -; Genomic_DNA.
DR   EMBL; BC035857; AAH35857.1; -; mRNA.
DR   EMBL; BC053550; AAH53550.1; -; mRNA.
DR   EMBL; AJ844621; CAH59743.1; -; mRNA.
DR   CCDS; CCDS1307.1; -.
DR   RefSeq; NP_004896.1; NM_004905.2.
DR   PDB; 1PRX; X-ray; 2.00 A; A/B=1-224.
DR   PDB; 5B6M; X-ray; 2.50 A; A/B/C/D/E/F=1-224.
DR   PDB; 5B6N; X-ray; 2.90 A; A/B/C/D/E/F=1-224.
DR   PDBsum; 1PRX; -.
DR   PDBsum; 5B6M; -.
DR   PDBsum; 5B6N; -.
DR   BMRB; P30041; -.
DR   SMR; P30041; -.
DR   BioGRID; 114956; 167.
DR   IntAct; P30041; 40.
DR   MINT; P30041; -.
DR   STRING; 9606.ENSP00000342026; -.
DR   ChEMBL; CHEMBL4295741; -.
DR   DrugBank; DB03814; 2-(N-morpholino)ethanesulfonic acid.
DR   DrugBank; DB09130; Copper.
DR   SwissLipids; SLP:000001691; -.
DR   MoonDB; P30041; Curated.
DR   MoonProt; P30041; -.
DR   PeroxiBase; 4426; Hs1CysPrx01.
DR   CarbonylDB; P30041; -.
DR   iPTMnet; P30041; -.
DR   MetOSite; P30041; -.
DR   PhosphoSitePlus; P30041; -.
DR   SwissPalm; P30041; -.
DR   BioMuta; PRDX6; -.
DR   DMDM; 1718024; -.
DR   DOSAC-COBS-2DPAGE; P30041; -.
DR   OGP; P30041; -.
DR   REPRODUCTION-2DPAGE; IPI00220301; -.
DR   REPRODUCTION-2DPAGE; P30041; -.
DR   SWISS-2DPAGE; P30041; -.
DR   CPTAC; CPTAC-117; -.
DR   CPTAC; CPTAC-118; -.
DR   EPD; P30041; -.
DR   jPOST; P30041; -.
DR   MassIVE; P30041; -.
DR   PaxDb; P30041; -.
DR   PeptideAtlas; P30041; -.
DR   PRIDE; P30041; -.
DR   ProteomicsDB; 54620; -.
DR   TopDownProteomics; P30041; -.
DR   Antibodypedia; 1681; 611 antibodies.
DR   DNASU; 9588; -.
DR   Ensembl; ENST00000340385; ENSP00000342026; ENSG00000117592.
DR   GeneID; 9588; -.
DR   KEGG; hsa:9588; -.
DR   CTD; 9588; -.
DR   DisGeNET; 9588; -.
DR   GeneCards; PRDX6; -.
DR   HGNC; HGNC:16753; PRDX6.
DR   HPA; ENSG00000117592; Low tissue specificity.
DR   MIM; 602316; gene.
DR   neXtProt; NX_P30041; -.
DR   OpenTargets; ENSG00000117592; -.
DR   PharmGKB; PA134992760; -.
DR   VEuPathDB; HostDB:ENSG00000117592.8; -.
DR   eggNOG; KOG0854; Eukaryota.
DR   GeneTree; ENSGT00550000074794; -.
DR   HOGENOM; CLU_042529_4_1_1; -.
DR   InParanoid; P30041; -.
DR   OMA; IPLTCRA; -.
DR   OrthoDB; 1129256at2759; -.
DR   PhylomeDB; P30041; -.
DR   TreeFam; TF105183; -.
DR   BioCyc; MetaCyc:HS04152-MONOMER; -.
DR   BRENDA; 1.11.1.15; 2681.
DR   PathwayCommons; P30041; -.
DR   Reactome; R-HSA-3299685; Detoxification of Reactive Oxygen Species.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   SIGNOR; P30041; -.
DR   BioGRID-ORCS; 9588; 15 hits in 992 CRISPR screens.
DR   ChiTaRS; PRDX6; human.
DR   EvolutionaryTrace; P30041; -.
DR   GeneWiki; PRDX6; -.
DR   GenomeRNAi; 9588; -.
DR   Pharos; P30041; Tbio.
DR   PRO; PR:P30041; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; P30041; protein.
DR   Bgee; ENSG00000117592; Expressed in amniotic fluid and 251 other tissues.
DR   ExpressionAtlas; P30041; baseline and differential.
DR   Genevisible; P30041; HS.
DR   GO; GO:0035578; C:azurophil granule lumen; TAS:Reactome.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IBA:GO_Central.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; HDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; IBA:GO_Central.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB.
DR   GO; GO:0047184; F:1-acylglycerophosphocholine O-acyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0045296; F:cadherin binding; HDA:BHF-UCL.
DR   GO; GO:0047499; F:calcium-independent phospholipase A2 activity; IMP:CAFA.
DR   GO; GO:0004602; F:glutathione peroxidase activity; IMP:CAFA.
DR   GO; GO:0042802; F:identical protein binding; IMP:CAFA.
DR   GO; GO:0051920; F:peroxiredoxin activity; IEA:InterPro.
DR   GO; GO:0004623; F:phospholipase A2 activity; IDA:UniProtKB.
DR   GO; GO:0102567; F:phospholipase A2 activity (consuming 1,2-dipalmitoylphosphatidylcholine); IEA:UniProtKB-EC.
DR   GO; GO:0102568; F:phospholipase A2 activity consuming 1,2-dioleoylphosphatidylethanolamine); IEA:UniProtKB-EC.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0045454; P:cell redox homeostasis; IBA:GO_Central.
DR   GO; GO:0098869; P:cellular oxidant detoxification; IMP:CAFA.
DR   GO; GO:0034599; P:cellular response to oxidative stress; TAS:Reactome.
DR   GO; GO:0046475; P:glycerophospholipid catabolic process; IMP:CAFA.
DR   GO; GO:0042744; P:hydrogen peroxide catabolic process; IEA:Ensembl.
DR   GO; GO:0043312; P:neutrophil degranulation; TAS:Reactome.
DR   GO; GO:0048026; P:positive regulation of mRNA splicing, via spliceosome; IGI:UniProtKB.
DR   GO; GO:0006979; P:response to oxidative stress; IMP:CAFA.
DR   Gene3D; 3.40.30.10; -; 1.
DR   InterPro; IPR000866; AhpC/TSA.
DR   InterPro; IPR024706; Peroxiredoxin_AhpC-typ.
DR   InterPro; IPR019479; Peroxiredoxin_C.
DR   InterPro; IPR036249; Thioredoxin-like_sf.
DR   InterPro; IPR013766; Thioredoxin_domain.
DR   Pfam; PF10417; 1-cysPrx_C; 1.
DR   Pfam; PF00578; AhpC-TSA; 1.
DR   PIRSF; PIRSF000239; AHPC; 1.
DR   SUPFAM; SSF52833; SSF52833; 1.
DR   PROSITE; PS51352; THIOREDOXIN_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Antioxidant; Cytoplasm;
KW   Direct protein sequencing; Hydrolase; Lipid degradation; Lipid metabolism;
KW   Lysosome; Multifunctional enzyme; Oxidoreductase; Peroxidase;
KW   Phosphoprotein; Redox-active center; Reference proteome; Transferase.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000269|PubMed:12665801,
FT                   ECO:0000269|PubMed:1286669, ECO:0000269|PubMed:8313871,
FT                   ECO:0000269|Ref.11, ECO:0007744|PubMed:22223895,
FT                   ECO:0007744|PubMed:25944712"
FT   CHAIN           2..224
FT                   /note="Peroxiredoxin-6"
FT                   /id="PRO_0000135102"
FT   DOMAIN          5..169
FT                   /note="Thioredoxin"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00691"
FT   REGION          31..40
FT                   /note="Required and sufficient for targeting to lysosomes
FT                   and lamellar bodies"
FT                   /evidence="ECO:0000250|UniProtKB:O35244"
FT   ACT_SITE        47
FT                   /note="Cysteine sulfenic acid (-SOH) intermediate; for
FT                   peroxidase activity"
FT                   /evidence="ECO:0000269|PubMed:10893423,
FT                   ECO:0000269|PubMed:9497358, ECO:0000269|PubMed:9587003"
FT   ACT_SITE        140
FT                   /note="For phospholipase activity"
FT                   /evidence="ECO:0000250|UniProtKB:O35244"
FT   SITE            32
FT                   /note="Important for phospholipase activity"
FT                   /evidence="ECO:0000305|PubMed:10893423"
FT   MOD_RES         44
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
FT   MOD_RES         63
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         89
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:15592455"
FT   MOD_RES         177
FT                   /note="Phosphothreonine; by MAPK"
FT                   /evidence="ECO:0000250|UniProtKB:O35244"
FT   MOD_RES         209
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         209
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:O08709"
FT   MUTAGEN         32
FT                   /note="S->A: Loss of phospholipase activity, but no effect
FT                   on peroxidase activity."
FT                   /evidence="ECO:0000269|PubMed:9497358"
FT   MUTAGEN         47
FT                   /note="C->S: Loss of peroxidase activity, but no effect on
FT                   phospholipase activity."
FT                   /evidence="ECO:0000269|PubMed:9497358"
FT   STRAND          15..18
FT                   /evidence="ECO:0007744|PDB:1PRX"
FT   STRAND          21..24
FT                   /evidence="ECO:0007744|PDB:1PRX"
FT   HELIX           25..29
FT                   /evidence="ECO:0007744|PDB:1PRX"
FT   STRAND          32..40
FT                   /evidence="ECO:0007744|PDB:1PRX"
FT   HELIX           45..62
FT                   /evidence="ECO:0007744|PDB:1PRX"
FT   TURN            63..65
FT                   /evidence="ECO:0007744|PDB:1PRX"
FT   STRAND          66..74
FT                   /evidence="ECO:0007744|PDB:1PRX"
FT   HELIX           76..89
FT                   /evidence="ECO:0007744|PDB:1PRX"
FT   STRAND          102..104
FT                   /evidence="ECO:0007744|PDB:1PRX"
FT   HELIX           109..113
FT                   /evidence="ECO:0007744|PDB:1PRX"
FT   STRAND          117..122
FT                   /evidence="ECO:0007744|PDB:5B6M"
FT   STRAND          124..126
FT                   /evidence="ECO:0007744|PDB:1PRX"
FT   STRAND          128..130
FT                   /evidence="ECO:0007744|PDB:5B6M"
FT   STRAND          133..137
FT                   /evidence="ECO:0007744|PDB:1PRX"
FT   STRAND          141..148
FT                   /evidence="ECO:0007744|PDB:1PRX"
FT   STRAND          151..153
FT                   /evidence="ECO:0007744|PDB:5B6N"
FT   HELIX           157..173
FT                   /evidence="ECO:0007744|PDB:1PRX"
FT   STRAND          175..177
FT                   /evidence="ECO:0007744|PDB:1PRX"
FT   STRAND          187..189
FT                   /evidence="ECO:0007744|PDB:1PRX"
FT   HELIX           195..201
FT                   /evidence="ECO:0007744|PDB:1PRX"
FT   STRAND          219..221
FT                   /evidence="ECO:0007744|PDB:1PRX"
SQ   SEQUENCE   224 AA;  25035 MW;  017D955F0FEEDFBC CRC64;
     MPGGLLLGDV APNFEANTTV GRIRFHDFLG DSWGILFSHP RDFTPVCTTE LGRAAKLAPE
     FAKRNVKLIA LSIDSVEDHL AWSKDINAYN CEEPTEKLPF PIIDDRNREL AILLGMLDPA
     EKDEKGMPVT ARVVFVFGPD KKLKLSILYP ATTGRNFDEI LRVVISLQLT AEKRVATPVD
     WKDGDSVMVL PTIPEEEAKK LFPKGVFTKE LPSGKKYLRY TPQP
//
